Replaces Prod. #: ALX-270-302
Negative control compound for the histone deacetylase (HDAC) inhibitor scriptaid (Prod. No. BML-GR326).
Product Details
| Alternative Name: | 4-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutanamide |
| |
| Formula: | C16H14N2O4 |
| |
| MW: | 298.3 |
| |
| Source: | Synthetic. |
| |
| CAS: | 300816-11-9 |
| |
| Purity: | ≥97% (TLC) |
| |
| Appearance: | Yellow to off-white solid. |
| |
| Solubility: | Soluble in DMSO (4mg/ml) or ethanol (0.3mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C. |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition: M.R. Davis, et al.; BMC Cancer
16, 316 (2016),
Application(s): Cell culture,
Abstract;
Full Text
A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library: G.H. Su, et al.; Cancer Res.
60, 3137 (2000),
Abstract;
Full Text
Related Products
